These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6190290)

  • 1. Candicidin treatment of prostatism: a prospective double-blind placebo-controlled study.
    Jensen KM; Madsen PO
    Urol Res; 1983; 11(1):7-10. PubMed ID: 6190290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candicidin in treatment of benign prostatic hypertrophy.
    Madsen PO; Dørflinger T; Frimodt-Møller PC; Jensen KM
    J Urol; 1984 Dec; 132(6):1235-8. PubMed ID: 6209428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy.
    Abrams PH
    Br J Urol; 1977 Feb; 49(1):67-71. PubMed ID: 65196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candicidin: physiologic effect on prostate.
    Sporer A; Cohen S; Kamat MH; Seebode JJ
    Urology; 1975 Sep; 6(3):298-304. PubMed ID: 51533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of candicidin in benign prostatic hypertrophy.
    Orkin LA
    Urology; 1974 Jul; 4(1):80-4. PubMed ID: 21322990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Candicidin treatment of benign hypertrophy of the prostate].
    Jensen SK; Hammen S
    Ugeskr Laeger; 1982 Jan; 144(1):26-7. PubMed ID: 6175063
    [No Abstract]   [Full Text] [Related]  

  • 7. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group.
    Fawzy A; Vashi V; Chung M; Dias N; Gaffney M
    Urology; 1999 Feb; 53(2):329-35. PubMed ID: 9933049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of bromocriptine in benign prostatic hypertrophy. A double-blind study.
    Van Poppel H; Boeckx G; Westelinck KJ; Vereecken RL; Baert L
    Br J Urol; 1987 Aug; 60(2):150-2. PubMed ID: 2444308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
    Safarinejad MR
    J Herb Pharmacother; 2005; 5(4):1-11. PubMed ID: 16635963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study.
    Narayan P; Trachtenberg J; Lepor H; Debruyne FM; Tewari A; Stone N; Das S; Jimenez-Cruz JF; Shearer R; Klimberg I; Schellhammer PF; Costello AJ
    Urology; 1996 Apr; 47(4):497-504. PubMed ID: 8638357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of raveron and levorin on urination recovery in prostatic adenoma and chronic prostatitis].
    Savin VF; Antonov NM; Arkannikov AB
    Urol Nefrol (Mosk); 1982; (2):22-4. PubMed ID: 6177084
    [No Abstract]   [Full Text] [Related]  

  • 19. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
    Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
    BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.